Treatment of rheumatoid arthritis with T-614:a multicenter,randomized,double blind,placebo-controlled trial
- VernacularTitle:艾拉莫德治疗类风湿关节炎多中心随机双盲安慰剂对照研究
- Author:
Jia-Lin TENG
;
Liang-Jing LV
;
Chun-De BAO
;
Xing-Hai HAN
;
Ling-Yun SUN
;
Jian-Hua XU
;
Xing-Fu LI
;
Hua-Xiang WU
;
- Publication Type:Journal Article
- Keywords:
Arthritis,rheumatoid;
Randomized controlled trial;
T-614
- From:
Chinese Journal of Rheumatology
2003;0(08):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the efficacy and safety of T-614 in treating rheumatoid arthritis(RA). Methods Two hundred and eighty patients with active RA were randomly allocated to 3 groups:T-614 50 mg each day,25 mg each day or placebo.Clinical and laboratory parameters were analyzed at baseline,2,4,6,12, 18 and 24 weeks.Results The ACR response rate was significantly higher in the T-614 treatment group com- pared with the placebo group during the first 6 weeks.After 24 weeks,25 mg/d,50 mg/d dosage group and the placebo group showed 39.1%,61.3% and 24.2% in ACR20,23.9%,31.2% and 7.4% in ACR50 respectively.A time-response in ACR response after 24 weeks was observed,with clear superiority of the 25 mg/d and 50 mg/d dosage groups compared to the placebo,and 50 mg/d dosage group compared to 25 mg/d dosage group(P
